Dexamethasone Sodium Phosphate in Xerostomia: NCT07802977 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Completed
Recruitment status
10
Planned enrollment
2022-07-30
Primary-completion proxy
Executive view
NCT07802977 evaluates Dexamethasone Sodium Phosphate in Xerostomia. The disclosed sponsor is University of California, Davis, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Number of Missed or Delayed Days of Radiation Therapy Due to Steroid Injection, assessed over From first steroid injection through completion of radiation therapy, up to 6 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07802977 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Xerostomia landscape. Drug & Asset MCP drug_fetch was queried for Dexamethasone Sodium Phosphate, while Company & Deal Intelligence MCP organization_fetch was queried for University of California, Davis.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07802977 | Dexamethasone Sodium Phosphate | Phase 1 / Completed | University of California, Davis | United States | Number of Missed or Delayed Days of Radiation Therapy Due to Steroid Injection From first steroid injection through completion of radiation therapy… | 2022-07-30 |
| NCT07801157 | Phenytoin | Not Applicable / Completed | Mansoura University | Egypt | Postoperative Wound Healing Score Postoperative day 1, week 1, week 2, month 1, month 3, and month 6 | 2025-12-01 |
| NCT07799077 | Paclitaxel | Phase 2 / Not yet recruiting | The Fourth Hospital of Hebei Medical University | China | Pathological Complete Response (pCR) rate Assessed via surgical pathology (4-6 weeks post-neoadjuvant therapy) | 2027-12-31 |
| NCT07796789 | Megestrol Acetate | Phase 3 / Recruiting | Sun Yat-Sen University | China | Proportion of Patients With >5% Weight Loss From Baseline at Day 28 After Completion of Radiotherapy Day 28 after completion of radiotherapy | 2027-08-30 |
| NCT07797881 | PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical) | Phase 2 / Not yet recruiting | Sichuan Baili Pharmaceuticals Co.,Ltd | China | Complete Response Rate(CRR) Up to approximately 24 months | 2030-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07802977 is a Phase 1, completed study with 10 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Number of Missed or Delayed Days of Radiation Therapy Due to Steroid Injection” over “From first steroid injection through completion of radiation therapy, up to 6 weeks.” The retrieved endpoint description is: Primary endpoint: Missed or delayed days of RT due to steroid injection. Count of radiation therapy treatment days that were missed or delayed as a direct result of the intraparenchymal dexamethasone injection procedure. To be assessed at every patient encounter..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 10 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
4 recent result records were selected as contextual evidence for Xerostomia. These records do not establish direct evidence for NCT07802977 unless the registration number matches.
Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas
Phase 1/2; n=26; Safety of Abemaciclib + Ramucirumab = 10 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04921904
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Phase 2; n=9; CR = 0 participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05119296
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
Phase 2; n=34; Histologic Response to Metformin: P-Value = 0.715; Histologic Response to Metformin: P-Value = 0.715 Source: https://clinicaltrials.gov/ct2/show/results/NCT05237960
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Dexamethasone Sodium Phosphate is indexed as Small molecule drug with GR biology and a global stage of Approved. The asset profile lists Merck & Co., Inc. as an originator or developer.
University of California, Davis is indexed in United States with the website http://www.ucdavis.edu. UC Davis is a public university that offers certificates and courses including online classes for adults and non-traditional learners. The record lists 27 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Dexamethasone Sodium Phosphate is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07802977
Protocol source: https://clinicaltrials.gov/study/NCT07802977
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Dexamethasone Sodium Phosphate in Xerostomia is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Number of Missed or Delayed Days of Radiation Therapy Due to Steroid Injection and 2022-07-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
